Preferential Potentiation of Topoisomerase I Poison Cytotoxicity by PARP Inhibition in S Phase

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Jul 9

PMID 25003660

Citations 21

Authors

P Znojek

E Willmore

N J Curtin

Affiliations

Soon will be listed here.

Abstract

Background: Topoisomerase I (Topo I) poisons (e.g., camptothecin (CPT)), used to treat cancer, cause DNA breaks that are most cytotoxic during S phase. PARP-1 promotes DNA repair and PARP inhibitors (PARPi) sensitise cells to Topo I poisons. We aimed to determine whether chemosensitisation is also S phase specific using rucaparib, a potent PARPi in advanced clinical evaluation.

Methods: The impact of rucaparib, on CPT-induced cytotoxicity was measured in human colon cancer (LoVo) and leukaemic (K562) cells in asynchronous and cell cycle phase-separated cultures. Topoisomerase I and PARP levels and activity and the effect of rucaparib on DNA single-strand breaks (SSBs), double-strand breaks (DSBs) and collapsed replication fork induction and repair were determined in cell cycle phase-separated cells.

Results: The cytotoxicity of CPT was greatest during S phase, partially attributable to high Topo I activity, and rucaparib preferentially sensitised S-phase cells. Rucaparib increased CPT-induced DNA SSBs in all phases of the cell cycle, and increased DSB and γH2AX foci in S and G2, with γH2AX foci being highest in S-phase cells. Repair of SSBs and DSBs was most rapid during S then G2 phases and was substantially hindered by rucaparib.

Conclusions: Rucaparib preferentially sensitises S-phase cells by increasing the frequency of collapsed replication forks.

Citing Articles

Antitumor Effects of Tryptanthrin on Colorectal Cancer by Regulating the Mitogen-Activated Protein Kinase Signaling Pathway and Targeting Topo I and IDO1.

Lu S, Hou B, Wang T, Ma K, Huang A, Wu X ACS Omega. 2025; 10(3):3206-3221.

PMID: 39895716 PMC: 11780470. DOI: 10.1021/acsomega.4c11189.

Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.

Bardia A, Sun S, Thimmiah N, Coates J, Wu B, Abelman R Clin Cancer Res. 2024; 30(14):2917-2924.

PMID: 38709212 PMC: 11247314. DOI: 10.1158/1078-0432.CCR-24-0428.

Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.

Bitler B, Bailey C, Yamamoto T, McMellen A, Kim H, Watson Z Mol Carcinog. 2023; 62(11):1717-1730.

PMID: 37493106 PMC: 10592327. DOI: 10.1002/mc.23610.

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.

Cecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S Cancer Res Commun. 2023; 3(6):1113-1117.

PMID: 37377610 PMC: 10292219. DOI: 10.1158/2767-9764.CRC-22-0485.

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer.

Florkemeier I, Hillmann J, Weimer J, Hildebrandt J, Hedemann N, Rogmans C Int J Mol Sci. 2022; 23(18).

PMID: 36142413 PMC: 9505822. DOI: 10.3390/ijms231810503.

References

Bowman K, Newell D, Calvert A, Curtin N . Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer. 2001; 84(1):106-12. PMC: 2363607. DOI: 10.1054/bjoc.2000.1555. View

Olive P . Impact of the comet assay in radiobiology. Mutat Res. 2007; 681(1):13-23. DOI: 10.1016/j.mrrev.2007.11.001. View

Darzynkiewicz Z, Halicka D, Tanaka T . Cytometric assessment of DNA damage induced by DNA topoisomerase inhibitors. Methods Mol Biol. 2009; 582:145-53. PMC: 3873872. DOI: 10.1007/978-1-60761-340-4_12. View

Cooper S, Chen K, Ravi S . Thymidine block does not synchronize L1210 mouse leukaemic cells: implications for cell cycle control, cell cycle analysis and whole-culture synchronization. Cell Prolif. 2008; 41(1):156-67. PMC: 6495963. DOI: 10.1111/j.1365-2184.2007.00508.x. View

Plo I, Liao Z, Barcelo J, Kohlhagen G, Caldecott K, Weinfeld M . Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst). 2003; 2(10):1087-100. DOI: 10.1016/s1568-7864(03)00116-2. View

van der Zee A, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse P . P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 1991; 51(21):5915-20. View

Mormont M, Levi F . Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2002; 97(1):155-69. DOI: 10.1002/cncr.11040. View

Delaney C, Wang L, Kyle S, White A, Calvert A, Curtin N . Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000; 6(7):2860-7. View

Smith L, Willmore E, Austin C, Curtin N . The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res. 2005; 11(23):8449-57. DOI: 10.1158/1078-0432.CCR-05-1224. View

10.

DAmours D, Desnoyers S, DSilva I, Poirier G . Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999; 342 ( Pt 2):249-68. PMC: 1220459. View

11.

Kummar S, Chen A, Ji J, Zhang Y, Reid J, Ames M . Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011; 71(17):5626-34. PMC: 3166628. DOI: 10.1158/0008-5472.CAN-11-1227. View

12.

Tsavaris N, Lazaris A, Kosmas C, Gouveris P, Kavantzas N, Kopterides P . Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2008; 64(2):391-8. PMC: 2688619. DOI: 10.1007/s00280-008-0886-4. View

13.

Drewinko B, Romsdahl M, Yang L, Ahearn M, Trujillo J . Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976; 36(2 Pt 1):467-75. View

14.

Rich T, Shelton 3rd C, Kirichenko A, Straume M . Chronomodulated chemotherapy and irradiation: an idea whose time has come?. Chronobiol Int. 2002; 19(1):191-205. DOI: 10.1081/cbi-120002598. View

15.

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

16.

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-7. DOI: 10.1016/s0140-6736(00)02034-1. View

17.

Pfister T, Reinhold W, Agama K, Gupta S, Khin S, Kinders R . Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther. 2009; 8(7):1878-84. PMC: 2728499. DOI: 10.1158/1535-7163.MCT-09-0016. View

18.

Calabrese C, Almassy R, Barton S, Batey M, Calvert A, Canan-Koch S . Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004; 96(1):56-67. DOI: 10.1093/jnci/djh005. View

19.

Bryant H, Petermann E, Schultz N, Jemth A, Loseva O, Issaeva N . PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009; 28(17):2601-15. PMC: 2738702. DOI: 10.1038/emboj.2009.206. View

20.

Miura K, Sakata K, Someya M, Matsumoto Y, Matsumoto H, Takahashi A . The combination of olaparib and camptothecin for effective radiosensitization. Radiat Oncol. 2012; 7:62. PMC: 3430568. DOI: 10.1186/1748-717X-7-62. View